Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.
Biora Therapeutics develops smart pill-based therapeutic delivery platforms, including BioJet™, an orally ingestible liquid jet technology for needle-free delivery of large molecules, and NaviCap™, a targeted oral delivery platform for colon-focused treatment of inflammatory bowel disease. BIOR news has centered on platform development, drug-delivery presentations, pharma collaborator activity, clinical and regulatory updates, and operating and financial results.
Company developments also include capital-structure and governance matters tied to Biora’s court-supervised restructuring. In 2025, Biora completed the restructuring, emerged as a privately held company, and cancelled its existing common shares under its plan of reorganization.
Biora Therapeutics presented new clinical data on its NaviCap™ platform at the Digestive Disease Week 2024 conference. The studies demonstrated the device's ability to deliver therapeutics directly to the colon in varied gastrointestinal conditions and eating schedules. Conducted on 47 participants, including those with active ulcerative colitis (UC), the trials showed the device was well-tolerated, with no serious adverse events reported. The NaviCap uses GItrac™ technology to autonomously target locations in the GI tract, ensuring effective delivery. The findings suggest potential improvements in treating inflammatory bowel diseases.
Biora Therapeutics reported their Q1 2024 financial results and provided a corporate update. They have completed dosing all patients in the clinical trial for BT-600, with results expected in late Q2 2024. Interim results showed consistent drug delivery to the colon. They will present NaviCap™ platform data at the DDW conference on May 19. Partnering progress for the BioJet oral delivery platform is ongoing. Financially, Biora raised $31 million in new capital and reported a net loss of $4.2 million for Q1 2024, an improvement from a $17.4 million net loss in Q1 2023.
Biora Therapeutics, Inc. (Nasdaq: BIOR) will report financial results and provide a corporate update for Q1 2024 on May 15, 2024. The company focuses on therapeutic delivery and will host a webcast and conference call after the market close. Investors can access the call online for 60 days.
Biora Therapeutics, Inc. (Nasdaq: BIOR) will present clinical data on the device function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024. The presentation will include results of human device function studies in healthy volunteers and patients with UC. The abstract will be presented by Shaoying Nikki Lee, PhD, Director of Clinical and Translational Science at Biora Therapeutics, Inc.
Biora Therapeutics, Inc. (Nasdaq: BIOR) announces the completion of dosing for multiple-ascending dose cohorts in the clinical trial of BT-600 for potential treatment of ulcerative colitis. Final results expected in late Q2 2024. The trial evaluated daily doses of BT-600 for seven days at 5 mg and 10 mg tofacitinib or placebo in healthy adult participants. Positive interim results from the single-ascending dose portion have been previously shared.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.